On Cancer: Targeted Therapy

Share
Print
and/or
109 Blog posts found

In the News

Updates from SABCS 2019: Detection and Screening, Immunotherapy Advances, and Therapy Resistance

About two dozen MSK physicians and researchers shared their work at the world’s leading breast cancer conference, held annually in San Antonio.

A presentation stage at the San Antonio Breast Cancer Symposium.

In the Clinic

Targeted Drug Shows Promise Against HER2-Positive Breast Cancer That Stops Responding to Other Drugs

MSK medical oncologist Shanu Modi is the lead author of a new paper detailing the results from a phase II trial of a breast cancer drug called trastuzumab deruxtecan or DS-8201a. Results from this study were also presented at the San Antonio Breast Cancer Symposium.

Illustration of breast cancer cell

In the News

MSK Experts Report Advances in Lymphoma Treatment at the 2019 ASH Meeting

Learn more about the work of MSK lymphoma researchers being presented at the 2019 meeting of the American Society of Hematology.

Exterior shot of building at ASH meeting

Finding

Largest Study of Its Kind Reveals New Targetable Genetic Causes of the Rare Blood Disorder Histiocytosis

In an international study led by MSK, researchers reported finding key mutations driving the disease histiocytosis for nearly all of the people included.

Two images of a human torso show a reduction in tumors after treatment with targeted therapy.

Finding

Machine Learning May Help Classify Cancers of Unknown Primary

MSK investigators report a new tool that may help them determine the origin of some metastatic tumors, potentially leading to better targeted treatments.

Illustration of a magnifying glass and DNA sequences

In the Clinic

6 Breakthroughs That Are Changing Chemotherapy for People with Breast Cancer

Discover some of the latest innovations in chemotherapy for breast cancer.

MSK patient receiving chemotherapy

In The Clinic

FDA Approves Pexidartinib, a Targeted Therapy for a Tumor of the Joints

Pexidartinib is the first drug approved specifically to treat tenosynovial giant cell tumor.

Medical oncologist William Tap

Finding

Whether a BRCA Mutation Leads to Cancer Depends on Context, Study Finds

Sometimes a BRCA mutation is just along for the ride, rather than driving a tumor’s development.

Computational biologist Barry Taylor

In the Lab

Researchers Unravel the Biology of a Distinct Prostate Cancer Subtype

Mutations in a gene called FOXA1 are responsible for a distinct class of prostate cancer tumors, MSK researchers have found.

MSK cancer researchers Elizabeth Adams, Charles Sawyers, and Rohit Bose